<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25715318</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.</ArticleTitle><Pagination><StartPage>2723</StartPage><EndPage>2733</EndPage><MedlinePgn>2723-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1011975</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is the key pathogen for Hand, Foot, and Mouth Disease (HFMD) and can result in severe neurological complications and death among young children. Three inactivated-EV71 vaccines have gone through phase III clinical trials and have demonstrated good safety and efficacy. These vaccines will benefit young children under the threat of severe HFMD. However, the potential immunization-related compatibility for different enterovirus vaccines remains unclear, making it hard to include the EV71 vaccine in Expanded Program on Immunization (EPI). Here, we measured the neutralizing antibodies (NTAbs) against EV71, Coxsackievirus A16 (CA16) and Poliovirus from infants enrolled in those EV71 vaccine clinical trials. The results indicated that the levels of NTAb GMTs for EV71 increased significantly in all 3 vaccine groups (high, middle and low dosages, respectively) post-vaccination. Seroconversion ratios and Geometric mean fold increase were significantly higher in the vaccine groups (&#x2265; 7/9 and 8.9 &#xff5e; 228.1) than in the placebo group (&#x2264; 1/10 and 0.8 &#xff5e; 1.7, P &lt; 0.05). But no similar NTAb response trends were found in CA16 and 3 types of Poliovirus. The decrease of 3 types of Poliovirus NTAb GMTs and an increase of CA16 GMTs post-EV71-vaccination were found in vaccine and placebo groups. Further animal study on CA16 and poliovirus vaccine co-immunization or pre-immunization with EV71 vaccine in mice indicated that there was no NTAb cross-activity between EV71 and CA16/Poliovirus. Our research showed that inactivated-EV71 vaccine has good specific-neutralizing capacity and can be included in EPI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Zhifang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Changgui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rongcheng</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>b The Center for Disease Control and Prevention of the Guangxi Zhuang Autonomous Region ; Nanning , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fengcai</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>c Jiangsu Provincial Center for Disease Control and Prevention ; Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>a National Institutes for Food and Drug Control ; Beijing , China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">coxsackievirus A16 (CA16)</Keyword><Keyword MajorTopicYN="N">enterovirus 71 (EV71)</Keyword><Keyword MajorTopicYN="N">foot</Keyword><Keyword MajorTopicYN="N">hand</Keyword><Keyword MajorTopicYN="N">neutralizing antibody (NTAb)</Keyword><Keyword MajorTopicYN="N">poliovirus; vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25715318</ArticleId><ArticleId IdType="pmc">PMC4685687</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1011975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abu Bakar S,Chan YF,Lam SK. Outbreaks of enterovirus 71 infection. N Engl J Med 2000; 342:355&#x2013;6; PMID:10660400; http://dx.doi.org/10.1056/NEJM200002033420513</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200002033420513</ArticleId><ArticleId IdType="pubmed">10660400</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T,Lewthwaite P,Perera D,Cardosa MJ,McMinn P,Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10(11):778-90; PMID:20961813; http://dx.doi.org/10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH,Wong SC,Lewth waite P,Cardosa MJ,Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097-105; PMID:20965438; http://dx.doi.org/10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M,Chen ER,Hsu KH,Twu SJ,Chen KT,Tsai SF,Wang JR,Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-35; PMID:10498487; http://dx.doi.org/10.1056/NEJM199909233411301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P,Lindsay K,Perera D,Chan HM,Chan KP,Cardosa MJ. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol 2001; 75:7732-8; PMID:11462047; http://dx.doi.org/10.1128/JVI.75.16.7732-7738.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7732-7738.2001</ArticleId><ArticleId IdType="pmc">PMC115010</ArticleId><ArticleId IdType="pubmed">11462047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS,Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010; 9:149-56; PMID:20109026; http://dx.doi.org/10.1586/erv.09.152</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X,Huang X,Zhu S,Chen H,Yu Q,Wang H,Huo X,Zhou J,Wu Y,Yan D, et&#xa0;al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011; 6(9):e25662; PMID:21980521; http://dx.doi.org/10.1371/journal.pone.0025662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP,Liang ZL,Gao Q,Huang LR,Mao QY,Wen SQ,Liu Y,Yin WD,Li RC,Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30(22):3295-303; PMID:22426327; http://dx.doi.org/10.1016/j.vaccine.2012.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP,Liang ZL,Xia JL,Wu JY,Wang L,Song LF,Mao QY,Wen SQ,Huang RG,Hu YS, et al. . Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.J Infect Dis 2014; 209(1):46-55; http://dx.doi.org/10.1093/infdis/jit429</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F,Xu W,Xia J,Liang Z,Liu Y,Zhang X,Tan X,Wang L,Mao Q,Wu J, et al. . Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370(9):818-28; http://dx.doi.org/10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC,Wang JZ,Li XL,Liang ZL,Ge HM,Meng FY,Mao QY,Zhang YT,Zhang ZY,Ji H, et al. . Reactogenicity and immunogenicity of an enterovirus 71 vaccine in chinese healthy children and infants. Pediatr Infect Dis J 2012; 31(11):1158-65; PMID:22926209; http://dx.doi.org/10.1097/INF.0b013e31826eba74</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e31826eba74</ArticleId><ArticleId IdType="pubmed">22926209</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC,Liang ZL,Li XL,Ge HM,Meng FY,Mao QY,Zhang YT,Hu YM,Zhang ZY,Li JX, et al. . Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381(9871):1037-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC,Meng FY,Li JX,Li XL,Mao QY,Tao H,Zhang YT,Yao X,Chu K,Chen QH, et al. . Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381(9882):2024-32; http://dx.doi.org/10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L,Zhang Y,Wang J,Zhao H,Jiang L,Che Y,Shi H,Li R,Mo Z,Huang T, et al. . Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013; 8(1): e54451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R,Liu L,Mo Z,Wang X,Xia J,Liang Z,Zhang Y,Li Y,Mao Q,Wang J, et al. . An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370(9):829-37; http://dx.doi.org/10.1056/NEJMoa1303224</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Regenmortel MHV, Fauquet CM, Bishop DHL, Carsten EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR, et al. (Eds.), Virus Taxonomy. Classification and Nomenclature of Viruses. Seventh Report of the ICTV. New York: Academic Press, 2000:657-73.</Citation></Reference><Reference><Citation>Juhela S,Hyoty H,Lonnrot M,Roivainen M,Simell O,Ilonen J.1998. Enterovirus infections and enterovirus specific T-cell responses ininfancy. J Med Virol 54:226-32; PMID:9515773; http://dx.doi.org/10.1002/(SICI)1096-9071(199803)54:3%3c226::AID-JMV14%3e3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199803)54:3%3c226::AID-JMV14%3e3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">9515773</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W,Wu S,Xiong Y,Li T,Wen Z,Yan M,Qin K,Liu Y,Wu J. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One 2014; 9(4):e96051; PMID:24776922; http://dx.doi.org/10.1371/journal.pone.0096051</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096051</ArticleId><ArticleId IdType="pmc">PMC4002479</ArticleId><ArticleId IdType="pubmed">24776922</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L,He Y,Yang H,Zhu J,Xu X,Dong J,Zhu Y,Jin Q. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol 2005; 43:3835-9; PMID:16081920; PMID:16081920; http://dx.doi.org/10.1128/JCM.43.8.3835-3839.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.8.3835-3839.2005</ArticleId><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS,Maher K,Kilpatrick DR,Pallansch MA. Molecular evolution 432 of the human enteroviruses: correlation of serotype with VP1 sequence and 433 application to picornavirus classification. J Virol 1999; 73:1941-8; PMID:9971773</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104435</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Mao QY, He P, Zhou C, Zhu XF, Zhang W, Lu FM, Liang ZL, Li FX, Wang JZ. Genetic characteristics of coxsakievirus A16 complete genome isolated in Beijing, 2008. 2010, 31(12):1437-38.</Citation></Reference><Reference><Citation>World heaith organization 
WHO recommendations for routine immunization&#x2013;summary tables. http://www.who.int/immunization/policy/immunization_schedules/en/</Citation></Reference><Reference><Citation>Cello J,Stranneg&#xe5;rd O,Svennerholm B. A study of the cellular immune response to enteroviruses in humans: identification of cross-reactive T cell epitopes on the structural proteins of enteroviruses. J Gen Virol 1996; 77:2097-108; PMID:8811009; http://dx.doi.org/10.1099/0022-1317-77-9-2097</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-77-9-2097</ArticleId><ArticleId IdType="pubmed">8811009</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuelson A,Forsgren M,Johansson B,Wahren B,Sa&#xa8;llberg M. Molecular basis for serological cross-reactivity between enteroviruses. Clin Diagn Lab Immunol 1994; 1:336-41; PMID:7496972</Citation><ArticleIdList><ArticleId IdType="pmc">PMC368258</ArticleId><ArticleId IdType="pubmed">7496972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y,Wen K,Pan Y,Wang Y,Che X,Wang B. Cross-reactivity of anti-EV71 IgM and neutralizing antibody in series sera of patients infected with Enterovirus 71 and Coxsackievirus A 16. J Immunoassay Immunochem 2011; 32(3):233-43; PMID:21574094; http://dx.doi.org/10.1080/15321819.2011.559297</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15321819.2011.559297</ArticleId><ArticleId IdType="pubmed">21574094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH,Liu CC,Chang JY,Jiang R,Hsieh YC,Tsao A,Wu CL,Huang JL,Fung CP,Hsieh SM, et al. . Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013; 8(11):e79783 e Collection 2013; http://dx.doi.org/10.1371/journal.pone.0079783</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Q,Yang C,Zhu K,Deng C,Zhu L,Wan J. Pre-existing heterologous immunity to poliovirus vaccination may mitigate severity of hand, food and mouth disease caused by EV71. BMC Proceedings 2011; 5(Suppl 1):P27; http://dx.doi.org/10.1186/1753-6561-5-s1-p27</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1753-6561-5-s1-p27</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovi T,Roivainen M. Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus.JClinMicrobiol 1993; 31(5):1083-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC262883</ArticleId><ArticleId IdType="pubmed">8388885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S,Tan X,Sun X,Lu G,Chen CC,Yan J,Liu J,Xu W,Gao GF. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population. J Immunol 2013; 191(4):1637-47; http://dx.doi.org/10.4049/jimmunol.1301439</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301439</ArticleId><ArticleId IdType="pubmed">23863902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu TC,Wang YF,Lee YP,Wang JR,Liu CC,Wang SM,Lei HY,Su IJ,Yu CK. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007; 81(19):10310-5. Epub 2007 Jul 11; http://dx.doi.org/10.1128/JVI.00372-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00372-07</ArticleId><ArticleId IdType="pmc">PMC2045469</ArticleId><ArticleId IdType="pubmed">17626076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y,Wen K,Pan Y,Wang Y,Che X,Wang B. Cross-reactivity of anti-EV71 IgM and neutralizing antibody in series sera of patients infected with Enterovirus 71 and Coxsackievirus A 16.J Immunoassay Immunochem 2011; 32(3):233-43; PMID:21574094; http://dx.doi.org/10.1080/15321819.2011.559297</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15321819.2011.559297</ArticleId><ArticleId IdType="pubmed">21574094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HM,Li CR,Liu YJ,Liu WL,Fu D,Xu LM,Xie JJ,Tan Y,Wang H,Chen XC, et al. . To investigate pathogen of hand, foot and mouth disease in Shenzhen in 2008. Chin J Exp Clin Virol 2009; 23:334-6;PMID:20387478</Citation><ArticleIdList><ArticleId IdType="pubmed">20387478</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H,Zhu YF,Qi X,Zhang YJ,Li L,Deng F,Wu B,Wang SJ,Zhu FC,Wang H. Analysis on the epidemiological and genetic characteristics of enterovirustype 71 and Coxsackie A16 virus infection in Jiangsu,China. Zhonghua Liu Xing Bing XueZaZhi 2009; 30:339-43; PMID:19731523</Citation><ArticleIdList><ArticleId IdType="pubmed">19731523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferson MJ,Bell SM. Outbreak of CoxsackievirusA16 hand, foot, and mouth disease in a child day care center. Am J Public Health 1991; 81:1675-6; PMID:1746672; http://dx.doi.org/10.2105/AJPH.81.12.1675</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.81.12.1675</ArticleId><ArticleId IdType="pmc">PMC1405294</ArticleId><ArticleId IdType="pubmed">1746672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendig JW,Fleming DM. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 1996; 6:R81-6; PMID:8664928</Citation><ArticleIdList><ArticleId IdType="pubmed">8664928</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol 2008; 49:103-12; PMID:19054914; http://dx.doi.org/10.1016/S1875-9572(08)60023-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60023-6</ArticleId><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang LW,Koh BK,Chan KP,Chua LT,James L,Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009; 38:106-12; PMID:19271036</Citation><ArticleIdList><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J,Luo Z,Wang J,Xu Z,Chen H,Fan D,N Gao,Ping G,Zhou Z,Zhang Y, et al. . Phylogenetic analysis of Enterovirus 71 circulating in Beijing, China from 2007 to 2009. PLoS One 2013; 8:e56318; PMID:23418551; http://dx.doi.org/10.1371/journal.pone.0056318</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056318</ArticleId><ArticleId IdType="pmc">PMC3572022</ArticleId><ArticleId IdType="pubmed">23418551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Qi S, Zhang X, Zhang Y, Liu L, Che Y, He Z, Zhao Y, Lu S, Yu W, Li Q Coxsackievirus A 16 infection does not interfere with the specific immune response induced by an enterovirus 71 inactivated vaccine in rhesus monkeys. Vaccine 2014; 32(35):4436-42. doi: 10.1016/j.vaccine.2014.06.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.062</ArticleId><ArticleId IdType="pubmed">24958699</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita I,Nakane M,Fenner F. Public health. Is polio eradication realistic? Science 2006; 312(5775):852-4; http://dx.doi.org/10.1126/science.1124959</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1124959</ArticleId><ArticleId IdType="pubmed">16690846</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization 
2012, Posting date. Polio case count. http://apps.who.int/immunization_monitoring/en/diseases/poliomyelitis/afpextract.cfm</Citation></Reference><Reference><Citation>Luo HM,Zhang Y,Wang XQ,Yu WZ,Wen N,Yan DM,Wang HQ,Wushouer F,Wang HB,Xu AQ, et al. . Identification and control of a poliomyelitis outbreak in Xinjiang, China. N Engl J Med 2013; 369(21):1981-90; http://dx.doi.org/10.1056/NEJMoa1303368</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303368</ArticleId><ArticleId IdType="pubmed">24256377</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C,Yang C,Wan J,Zhu L,Leng Q. Irregular poliovirus vaccination correlates to pulmonary edema of hand, foot, and mouth disease. Clin Vaccine Immunol 2011; 18(9): 1589- 90 Epub 2011 Jul 13; http://dx.doi.org/10.1128/CVI.05132-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05132-11</ArticleId><ArticleId IdType="pmc">PMC3165241</ArticleId><ArticleId IdType="pubmed">21752953</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylward B,Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine 2011; 29: Suppl 4:D80-D85; http://dx.doi.org/10.1016/j.vaccine.2011.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.005</ArticleId><ArticleId IdType="pubmed">22486981</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD,Ferguson M,Evans DM,Almond JW,Icenogle JP. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 1986; 67(Pt 7):1283-91; PMID:2425046; http://dx.doi.org/10.1099/0022-1317-67-7-1283</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-67-7-1283</ArticleId><ArticleId IdType="pubmed">2425046</ArticleId></ArticleIdList></Reference><Reference><Citation>Emini EA, Jameson BA,Lewis AJ,Larsen GR,Wimmer E. Poliovirusneutralizationepitopes: analysis and localization with neutralizing monoclonal antibodies. J Virol 1982; 43(3):997-1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC256210</ArticleId><ArticleId IdType="pubmed">6183443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz KN,Smith AD,Geisler SC,Cox S,Buontempo P,Skelton A,DeMartino J,Rozhon E,Schwartz J,Girijavallabhan V, et al. . Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 1997; 5(7):961-78; PMID:9261087; http://dx.doi.org/10.1016/S0969-2126(97)00249-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-2126(97)00249-9</ArticleId><ArticleId IdType="pubmed">9261087</ArticleId></ArticleIdList></Reference><Reference><Citation>Page GS,Mosser AG,Hogle JM,Filman DJ,Rueckert RR,Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol 1988; 62(5):1781-94; PMID:2451757</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253228</ArticleId><ArticleId IdType="pubmed">2451757</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG,Alonso S,Phoon MC,Ramachandran NP,Chow VT,Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007; 125(1):61-8; PMID:17222936; http://dx.doi.org/10.1016/j.virusres.2006.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H,Cifuente JO,Ashley RE,Conway JF,Makhov AM,Tano Y,Shimizu H,Nishimura Y,Hafenstein S. A strain-specific epitope of Enterovirus 71 identified by cryoEM of the complex with Fab from neutralizing antibody. J Virol 2013; 87(21):11363-70; PMID:23946455; http://dx.doi.org/10.1128/JVI.01926-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01926-13</ArticleId><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC,Chou AH,Lien SP,Lin HY,Liu SJ,Chang JY,Guo MS,Chow YH,Yang WS,Chang KH, et al. . Identification and characterization of a cross-neutralization epitope of Enterovirus71.Vaccine 2011; 29(26):4362-72; http://dx.doi.org/10.1016/j.vaccine.2011.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF,Jia Q,Khong WX,Yan B,Premanand B,Alonso S,Chow VT,Kwang J. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 2012; 7(1):e29751. Epub 2012 Jan 18; PMID:22279543; http://dx.doi.org/10.1371/journal.pone.0029751</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K,Poh CL,Fecondo J,Pourianfar H,Shaw J,Grollo L. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silicoapproach. Vaccine 2012; 30(Nov (49)):7105-10; PMID:23022400; http://dx.doi.org/10.1016/j.vaccine.2012.09.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J,Huang X,Liu Q,Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 2013; 31(17):2130-6; http://dx.doi.org/10.1016/j.vaccine.2013.02.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z,Mao Q,Gao Q,Li X,Dong C,Yu X,Yao X,Li F,Yin W,Li Q, et al. . Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29: 9668-74; PMID:22015395; http://dx.doi.org/10.1016/j.vaccine.2011.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Department of Immunization , Vaccines and Biologicals. Polio laboratory manual. 4th ed. Geneva: World Health Organization, 2004. (WHO/IVB/04.10.).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>